Literature DB >> 9576283

The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma.

Y Mita1, Y Aoyagi, M Yanagi, T Suda, Y Suzuki, H Asakura.   

Abstract

BACKGROUND: Measurements of serum concentrations of des-gamma-carboxy prothrombin (DCP) are widely used for diagnosing hepatocellular carcinoma (HCC). However, the DCP is not always sensitive enough to detect small HCCs. In the current study, the authors investigated the usefulness of DCP in the early diagnosis of HCC, using a more sensitive enzyme immunoassay than is conventionally employed.
METHODS: The authors examined 148 serum samples with DCP concentrations from a conventional assay of less than 100 mAU (arbitrary unit)/mL from 91 patients with HCC and 57 with cirrhosis. DCP concentrations were determined by a more sensitive enzyme immunoassay (ED-036 kit, Eisai Laboratory, Tokyo, Japan) with a minimal detection level of 10 mAU/mL. Ninety-one HCC patients had 43 solitary small HCCs (with a greatest dimension of less than 2 cm). Of these 43 HCCs, 12 were well differentiated.
RESULTS: The mean serum concentration of DCP in HCC (48.3 +/- 24.3, mean +/- standard deviation [SD]) was higher than in cirrhosis (20.3 +/- 10.3); this difference was statistically significant. When the tentative cutoff level of 40 mAU/mL (almost corresponding to the mean value + 2SD in patients with cirrhosis) was used as the level of discriminating HCC from cirrhosis, 62% of patients (56 of 91) with HCC had DCP values above this level (sensitivity). However, only three patients with cirrhosis had higher DCP levels. Thus, the specificity of this test was 95% (54 of 57 patients). The total accuracy was 74% (56 + 54/91 + 57). Twenty-three of 43 solitary small HCCs (53%) had DCP values above the cutoff level. Furthermore, 7 of 12 (58%) small, well-differentiated HCCs less than 2 cm in greatest dimension had higher DCP values.
CONCLUSIONS: The results of this study indicate that DCP determination by sensitive enzyme immunoassay is useful in the early diagnosis of HCC because a high specificity is maintained.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9576283     DOI: 10.1002/(sici)1097-0142(19980501)82:9<1643::aid-cncr8>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  42 in total

1.  Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

Authors:  Richard K Sterling; Elizabeth C Wright; Timothy R Morgan; Leonard B Seeff; John C Hoefs; Adrian M Di Bisceglie; Jules L Dienstag; Anna S Lok
Journal:  Am J Gastroenterol       Date:  2011-09-20       Impact factor: 10.864

Review 2.  Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china.

Authors:  Peipei Song; Jianjun Gao; Yoshinori Inagaki; Norihiro Kokudo; Kiyoshi Hasegawa; Yasuhiko Sugawara; Wei Tang
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

3.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

Review 4.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

5.  Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Yasuhiro Sone; Atsuyuki Maeda; Yuji Kaneoka
Journal:  Hepatol Int       Date:  2014-07-23       Impact factor: 6.047

6.  Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Seung In Seo; Hyoung Su Kim; Won Jin Kim; Woon Geon Shin; Doo Jin Kim; Kyung Ho Kim; Myoung Kuk Jang; Jin Heon Lee; Joo Seop Kim; Hak Yang Kim; Dong Joon Kim; Myung Seok Lee; Choong Kee Park
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

7.  Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma.

Authors:  Chaur-Shine Wang; Chih-Lin Lin; Hsi-Chang Lee; Kuan-Yang Chen; Ming-Feng Chiang; Hung-Sheng Chen; Tsung-Jung Lin; Li-Ying Liao
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

8.  The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Shuji Kanmura; Hirofumi Uto; Yuko Sato; Koutarou Kumagai; Fumisato Sasaki; Akihiro Moriuchi; Makoto Oketani; Akio Ido; Kenji Nagata; Katsuhiro Hayashi; Sherri O Stuver; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2009-12-09       Impact factor: 7.527

9.  Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein.

Authors:  R Cui; J He; F Zhang; B Wang; H Ding; H Shen; Y Li; X Chen
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Overexpression of sineoculis homeobox homolog 1 predicts poor prognosis of hepatocellular carcinoma.

Authors:  Jienan Kong; Xianchun Zhou; Shusen Liu; Tiefeng Jin; Yingshi Piao; Chao Liu; Zhenhua Lin
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.